Daa Pangenotypic Mavyret denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued an Experimental Denial for Mavyret

Mavyret (glecaprevir/pibrentasvir) holds FDA approval for treatment of chronic hepatitis C in adults and eligible pediatric patients, as specified in its current prescribing label. An "experimental" or "investigational" denial from Aetna for a standard, on-label use of Mavyret is almost always the result of a documentation gap — for example, the indication submitted did not clearly match the approved label language, the patient's age or weight profile was insufficiently documented, or the submission referenced an off-label use without adequate clinical support.

Because FDA approval is a matter of public record, this type of denial tends to be among the easiest to reverse on appeal when the use is genuinely on-label. The appeal strategy is to provide Aetna with the specific FDA label language confirming the indication, link it directly to the patient's documented diagnosis and clinical profile, and demonstrate that the prescriber's order falls within approved use.

## Federal Appeal Framework

• ACA Section 2719 / external review: Non-grandfathered Aetna commercial plans must offer independent external review by an accredited IRO after internal appeals are exhausted. The standard window is approximately four months from the denial notice; verify the exact deadline on your Explanation of Benefits. Expedited review (roughly 72 hours) is available when delay poses a serious health risk.
• ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review, including written disclosure of the specific policy language used to classify the treatment as experimental.

## Concrete Appeal Steps and Timeline

1. Request the full denial letter and the specific Aetna clinical policy provision classifying Mavyret as experimental for the submitted indication. 2. Retrieve the current FDA-approved prescribing information for Mavyret from the FDA's DailyMed database or the manufacturer. 3. File a Level 1 internal appeal within the plan-stated deadline, attaching the label excerpt confirming approval and the prescriber's attestation of on-label use. 4. If denied internally, escalate to external review before the deadline on the denial notice.

## Documentation to Gather

• Diagnosis confirmation: Hepatitis C genotype, viral load, and liver-disease staging linking the patient's diagnosis to the FDA-approved indication in the Mavyret label.
• FDA label excerpt: The relevant indication section of the current prescribing information confirming FDA approval for this use.
• Prescriber attestation: A letter from the treating provider confirming the order is on-label, citing the FDA-approved prescribing information and the applicable AASLD/IDSA hepatitis C guidance as support.
• Prior-treatment and clinical history: Documentation establishing that this is a recognized, standard-of-care treatment for this patient's hepatitis C genotype and clinical profile.

## Criteria-Mapping Structure

From (a) the Mavyret FDA-approved prescribing information and (b) Aetna's published experimental/investigational and hepatitis C clinical policies, create a side-by-side table: left column lists Aetna's stated reasons for the experimental classification; right column provides the label language, chart evidence, and guideline reference that refutes each reason. A clear, source-cited rebuttal is the most persuasive format for overturning a misapplied experimental denial.